Bristol-Myers Squibb Co (NYSE:BMY) Shares Purchased by Cetera Advisors LLC

Cetera Advisors LLC boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,648 shares of the biopharmaceutical company’s stock after purchasing an additional 481 shares during the quarter. Cetera Advisors LLC’s holdings in Bristol-Myers Squibb were worth $3,625,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Bath Savings Trust Co lifted its stake in shares of Bristol-Myers Squibb by 3.4% in the second quarter. Bath Savings Trust Co now owns 17,108 shares of the biopharmaceutical company’s stock worth $776,000 after buying an additional 568 shares in the last quarter. Boltwood Capital Management lifted its stake in shares of Bristol-Myers Squibb by 1.9% in the second quarter. Boltwood Capital Management now owns 21,626 shares of the biopharmaceutical company’s stock worth $981,000 after buying an additional 400 shares in the last quarter. Thomasville National Bank lifted its stake in shares of Bristol-Myers Squibb by 1.6% in the second quarter. Thomasville National Bank now owns 18,605 shares of the biopharmaceutical company’s stock worth $843,000 after buying an additional 293 shares in the last quarter. Private Asset Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 5.5% in the second quarter. Private Asset Management Inc. now owns 129,289 shares of the biopharmaceutical company’s stock worth $5,863,000 after buying an additional 6,775 shares in the last quarter. Finally, ELM Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 5.7% in the second quarter. ELM Advisors LLC now owns 7,358 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 400 shares in the last quarter. 80.90% of the stock is owned by hedge funds and other institutional investors.

Shares of BMY stock opened at $58.79 on Thursday. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. The firm’s 50-day moving average is $53.52 and its two-hundred day moving average is $48.46. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $59.17. The company has a market capitalization of $94.74 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 1.35 and a beta of 0.71.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. The company had revenue of $6.01 billion for the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.09 earnings per share. Sell-side analysts forecast that Bristol-Myers Squibb Co will post 4.33 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 2.79%. The ex-dividend date was Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

Several research firms have recently weighed in on BMY. UBS Group raised their price target on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 23rd. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target on the stock in a research note on Wednesday, August 14th. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Friday, October 25th. JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. Finally, Peel Hunt reissued a “buy” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, October 29th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Buy” and an average target price of $56.64.

In other news, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the sale, the senior vice president now directly owns 74,471 shares in the company, valued at $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: What does relative strength index mean?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.